论文部分内容阅读
目的：探讨可乐必妥治疗下呼吸道感染的临床疗效及安全性。方法：可乐必妥组２００ｍｇ，ｐｏ，ｂｉｄ，７～１４ｄ；希刻劳组２５０ｍｇ，ｐｏ，ｑｉｄ，７～１４ｄ，二组病例各为３０例。结果：可乐必妥组治愈１５例（５０．０％），显效１２例（４０．０％），进步２例（６．７％），无效１例（３．３％）。希刻劳组治愈１１例（３６．６％），显效１５例（５０．０％），进步２例（６．７％），无效２例（６．７％）。二组在细菌清除率和药物敏感性方面均无显著差异（Ｐ＞０．０５，９３．３％ｖｓ８１．８％；９３．３％ｖｓ８１．８％）。无明显不良反应。结论：可乐必妥是一种非常有效和安全的治疗下呼吸道感染的抗菌素
Objective: To investigate the clinical efficacy and safety of colabitration in the treatment of lower respiratory tract infections. Methods: Colabitone group 200mg, po, bid, 7 ~ 14d; Xijialuo group 250mg, po, qid, 7 ~ 14d, the two groups of 30 cases each. Results: Fifteen cases (50.0%) were cured by corticosteroid, 12 cases (40.0%) were markedly improved, 2 cases (6.7%) were improved, and 1 case (3.3%) was ineffective. Hickoryu group cured 11 cases (36.6%), markedly effective in 15 cases (50.0%), improved in 2 cases (6.7%), invalid in 2 cases (6.7%). There was no significant difference in bacterial clearance and drug sensitivity between the two groups (P> 0.05, 93.3% vs 81.8%; 93.3% vs 81.8%). No obvious adverse reactions. Conclusion: Colabilitir is a very effective and safe antibiotic for the treatment of lower respiratory tract infections